Immunome Inc. (IMNM)
NASDAQ · Healthcare
Immunome Inc. Operating Income 2023–2025
Immunome Inc. annual/quarterly operating income history and growth rate from 2023 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Immunome Inc. operating income for the quarter ending March 31, 2026 was -59.3 M, a 32.92% increase year-over-year.
- Immunome Inc. operating income for the twelve months ending March 31, 2026 was -210.6 M, a 7.42% decrease year-over-year.
- Immunome Inc. annual operating income for 2025 was -224.1 M, a 26.71% decrease from 2024.
- Immunome Inc. annual operating income for 2024 was -305.8 M, a 179.19% increase from 2023.
- Immunome Inc. annual operating income for 2023 was -109.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Immunome Inc. Operating Income — FAQ
Immunome Inc. (IMNM) operating income over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
What is Immunome Inc.'s operating income?
Immunome Inc. (IMNM) reported operating income of -$224M for fiscal 2025.
Where can I see IMNM's operating income history?
The chart and table above show Immunome Inc.'s operating income by year and by quarter, including the growth rate.